Oppenheimer downgrades Boston Scientific stock rating on growth concerns
Oppenheimer downgraded Boston Scientific (BSX) to Perform from Outperform due to growth concerns, citing weak Q3 results and a lack of expected growth in 2027. The stock is down 55.5% YTD to $42.43. BSX reported Q3 revenue of $5.14B, meeting expectations but missing EPS forecasts. Analysts lowered price targets and earnings estimates, citing a cyberattack's impact and declining product franchises. BSX's organic growth was 1.5% YOY, below guidance.
How this was made
The 30-second read
Why it matters
The downgrade reflects heightened concerns about organic growth and execution, likely prompting short‑term selling.
Market read
Analyst downgrade after earnings miss adds fresh negative sentiment to BSX and may affect med‑tech peers.
What to watch
Potential cost‑cutting measures and undervaluation noted by Fair Value analysis may support a longer‑term upside.
Background
Boston Scientific reported Q3 revenue near expectations but missed EPS guidance, and disclosed a cyber‑attack impact.
Ticker impact
Oppenheimer downgraded Boston Scientific to Perform after its Q3 results, citing lack of growth and execution concerns.
likely pressure as the market prices in the growth concerns and lower rating.
Analyst downgrade with specific growth concerns and recent earnings miss typically triggers sell‑offs.
Market effects
Medical device sector may face broader scrutiny as growth concerns surface for a major player.
U.S. healthcare stocks could see modest pullback in the short term.
Limited to investors with exposure to Boston Scientific and related med‑tech peers.
Counterpoint
If the downgrade overstates the growth risk, the stock could rebound on a bounce‑back narrative.
Key entities
- companyBoston Scientific Corp.
Medical device maker receiving a downgrade.
- analyst_firmOppenheimer
Downgraded BSX to Perform.
